These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9592935)

  • 1. [Optimization of bioavailability of pharmacons].
    Kata M; Aigner Z; Erös I
    Acta Pharm Hung; 1998 Mar; 68(2):107-11. PubMed ID: 9592935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A timely reassessment of early prediction in the bioavailability of orally administered drugs.
    Larsen T; Link A
    Angew Chem Int Ed Engl; 2005 Jul; 44(29):4432-4. PubMed ID: 15984039
    [No Abstract]   [Full Text] [Related]  

  • 3. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentials of chromatographic methods in assessing the bioavailability and the pharmacokinetics of drugs.
    de Zeeuw RA
    Pharmazie; 1981 Mar; 36(3):178-84. PubMed ID: 7279981
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drugs and the organism. II. Bioavailability].
    Pflegel P; Pfeifer S
    Pharmazie; 1980; 34(5-6):337-59. PubMed ID: 6893363
    [No Abstract]   [Full Text] [Related]  

  • 6. Selective optimization of side activities: the SOSA approach.
    Wermuth CG
    Drug Discov Today; 2006 Feb; 11(3-4):160-4. PubMed ID: 16533714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of drug distribution, entero-hepatic cycle, bioavailability].
    Bailly-Salins F; Woronoff-Lemsi MC
    Soins; 1998 Apr; (624):41-3. PubMed ID: 9633463
    [No Abstract]   [Full Text] [Related]  

  • 8. Building predictive ADMET models for early decisions in drug discovery.
    Penzotti JE; Landrum GA; Putta S
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):49-61. PubMed ID: 14982148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bioavailability of drugs--concepts and problems].
    Bekemeier H; Hirschelmann R
    Pharmazie; 1984 Jan; 39(1):59-62. PubMed ID: 6718470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing the cyclodextrin complexation of drugs and drug biovailability through addition of water-soluble polymers.
    Loftsson T
    Pharmazie; 1998 Nov; 53(11):733-40. PubMed ID: 9853355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective optimization of side activities: another way for drug discovery.
    Wermuth CG
    J Med Chem; 2004 Mar; 47(6):1303-14. PubMed ID: 14998318
    [No Abstract]   [Full Text] [Related]  

  • 12. The utility of cyclodextrins for enhancing oral bioavailability.
    Carrier RL; Miller LA; Ahmed I
    J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The importance of micronization in the design of dosage forms I. Theoretical and biopharmaceutical aspects].
    Antal I
    Acta Pharm Hung; 2006; 76(2):95-103. PubMed ID: 17094668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent advance in predicting oral bioavailability].
    Ma GL; Cheng YY
    Yao Xue Xue Bao; 2006 Oct; 41(10):917-20. PubMed ID: 17184106
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics and bioavailability.
    Wagner JG
    Triangle; 1975; 14(3-4):101-8. PubMed ID: 1209729
    [No Abstract]   [Full Text] [Related]  

  • 16. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin.
    Figueiras A; Carvalho RA; Ribeiro L; Torres-Labandeira JJ; Veiga FJ
    Eur J Pharm Biopharm; 2007 Sep; 67(2):531-9. PubMed ID: 17451924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic algorithm-optimized QSPR models for bioavailability, protein binding, and urinary excretion.
    Wang J; Krudy G; Xie XQ; Wu C; Holland G
    J Chem Inf Model; 2006; 46(6):2674-83. PubMed ID: 17125207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs in nursing: drug bioavailability.
    Brodie MJ
    Nursing (Lond); 1982 Aug; 2(4):107-9. PubMed ID: 6926570
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.